News

Adalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.

Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.

In our last article “Building a Patient Education Program” (May, page 82) we explored how a solid patient education program can keep patients, resources and revenue from falling through the cracks and what your practice needs to build a strong patient education program.

An old anti-aging concept was rediscovered with the renewed popularity of facial patches.

Korean facemasks are making their way from Asia to the US with great rapidity.

The digital beauty advisor is a digitized mirror providing personalized skin care information and day-to-day comparative health evaluations.

There are both unique nuances and cultural considerations to rejuvenating the skin of East Asian patients, according to one dermatologist.

The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.

Dermatologists trying to boost practice revenue might add a device in hopes of making a profit on a cosmetic option or a skincare product line sold through the practice.

A laser is a suitable mode of treatment for certain dermatologic conditions in pediatric patients; however, there are certain procedural aspects that physicians should consider when treating younger children.

Castle Creek Pharmaceuticals announced in June 2017 that the first patient had enrolled in its phase 2/3 study assessing the safety and efficacy of its pipeline diacerein 1% ointment to treat epidermolysis bullosa simplex.

In July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.

Procell Therapies has released the DermaPaddle, a device that combines micro-dermabrasion with micro-needling.

Merz Aesthetics has announced the U.S. launch of Mederma Quick Dry Oil, a product that helps reduce the appearance of scars, stretch marks, uneven skin tone and dry skin.

Ducray has introduced two products to help promote hair growth.

Glytone has released the Glytone Sunscreen Lotion Broad Specturm SPF 40 as a daily sunscreen to be used in combination with aesthetic procedures and treatments.

Qosmedix has launched a beauty blog, QOSMEtips on its e-commerce website.

Key publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist

A novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to dermatologist.

Dermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.

Emerging data suggest that atopic dermatitis is not just a skin disease. In terms of its impact on the whole patient and its potential for multi-organ involvement, it is a systemic disease, according to one dermatologist.

Teledermatology may play a role in skin cancer diagnsosis, an accumulating body of literature indicates, says one dermatologist.

A recent study suggests patients are bothered by seborrheic keratoses and are inclined to want the lesions removed. Dermatologist Gary Goldenberg talks about a new option in the pipeline and how best to treat these lesions with available therapies.

Nonthermal pulsed ultrasound (UltraShape, Syneron Candela) treatments significantly reduce flank fat, without pain, downtime and apparent risks, according to a study.

The goal of a tiered approach to acne is to improve both the patient’s acne and quality of life, while promoting responsible use of antibiotics.

Many dermatologists use spironolactone as a treatment in conjunction with traditional therapies, birth control and other hormonal modalities to help with the hormonal component of acne in adult women.

The clinical presentation of acne vulgaris in darker-skinned individuals differs in many ways from the white population, including some specific exacerbating factors that are due to cultural skin and hair-care practices.

The tetracycline-derived antibiotic sarecycline from Allergan plc and Paratek Pharmaceuticals Inc. for the treatment of moderate-to-severe acne has been found effective and safe, according to the results of two phase 3 trials.

Atopic dermatitis (AD) is one of the most common skin conditions treated by dermatologists. As such, articles on atopic dermatitis tend to be some of the most popular Dermatology Times content. These are the top three AD articles.

When it comes to treating atopic dermatitis in non-white racial ethnic groups, there are variations in prevalence, genetic factors and clinical presentation.